Kyle Rose

Stock Analyst at Canaccord Genuity

(2.60)
# 2,126
Out of 5,120 analysts
115
Total ratings
51.61%
Success rate
13.24%
Average return

Stocks Rated by Kyle Rose

Insulet
Dec 17, 2025
Maintains: Buy
Price Target: $432$450
Current: $256.62
Upside: +75.36%
Smith & Nephew
Feb 26, 2025
Maintains: Hold
Price Target: $27
Current: $34.26
Upside: -21.19%
Stryker
Jan 29, 2025
Maintains: Buy
Price Target: $420$435
Current: $368.14
Upside: +18.16%
Globus Medical
Dec 20, 2023
Maintains: Buy
Price Target: $67$71
Current: $89.70
Upside: -20.85%
Enovis
Dec 20, 2023
Maintains: Buy
Price Target: $65$71
Current: $22.17
Upside: +220.25%
InMode
Oct 13, 2023
Downgrades: Hold
Price Target: $55$22
Current: $16.62
Upside: +32.37%
The Beauty Health Company
Aug 25, 2023
Assumes: Buy
Price Target: $10
Current: $1.50
Upside: +566.67%
Alphatec Holdings
Aug 4, 2023
Maintains: Buy
Price Target: $17$22
Current: $14.49
Upside: +51.83%
DexCom
Jul 28, 2023
Maintains: Buy
Price Target: $135$150
Current: $72.53
Upside: +106.81%
Vicarious Surgical
May 31, 2023
Maintains: Buy
Price Target: $360$270
Current: $2.09
Upside: +12,818.66%
Maintains: Buy
Price Target: $24$27
Current: $16.37
Upside: +64.94%
Reiterates: Buy
Price Target: $15
Current: $0.95
Upside: +1,487.30%
Reiterates: Buy
Price Target: $15
Current: $35.02
Upside: -57.17%
Maintains: Market Perform
Price Target: $125$122
Current: $173.18
Upside: -29.55%
Upgrades: Buy
Price Target: $3$4
Current: $5.69
Upside: -29.70%
Downgrades: Hold
Price Target: n/a
Current: $8.21
Upside: -
Downgrades: Hold
Price Target: $165$125
Current: $86.22
Upside: +44.98%